Tianjin University

Hainan Lingkang Pharmaceutical Co., Ltd

Nantong Licheng Biological Engineering Co. Ltd

Nankai University

Zhejiang Huakang Pharmaceutical Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co. Ltd.

Accendatech Co. Ltd.

Junbo Gong

Baohong Hou

Qiuxiang Yin

Jingkang Wang

Linggang Tao

Ying Bao

Chuang Xie

Qinqing Gu

Jun Lv

Hongxun Hao

Shichao Du

Yongli Wang

Kaifei Zhao

Mian Li

Yue Chen

Wulong Yang

Qiang Wu

Qi Wang

Jiangbo Li

Duanming Tan

Yi Sun

Chuanjiang Qiu

Fang He

Xiaohua Wu

Feng Jin

Jie Qi

Guiyan Wang

Zhonghua Li

Xinghua Zhu

Mingxuan Li

Jiahui Li

Haiyan Xi

Shiping Tang

Mingyang Chen

Songgu Wu

Xiaopeng Song

Liting Liao

Xin Pan

Ziyuan Di

Zhongshi Liu

Zhihong Sun

A hydrate of dimethylaminomicheliolide fumarate has a crystal form D, is high in crystallinity, smooth in particle surface, free of coalescence, high in bulk density and good in flowability, and has good stability and good reproducibility. Its preparation method includes: under a stirring action, adding dimethylamine micheliolide and fumaric acid into a mixed solvent system having a constant temperature of 30° C.-70° C. for reaction crystallization; and filtering after the reaction is finished, and drying filtered solid at normal pressure to obtain the crystal form D of the dimethylaminomicheliolide fumarate.

Hydrate of dimethylaminomicheliolide fumarate and preparation method therefor and use thereof

The present disclosure provides a technology field of caking of crystal particles, and in particular relates to a method for predicting a critical caking cycle of crystal particle. The method includes: establishing a CHS crystal bridge growth model database of a crystal particle with a same type of crystal particle to be predicted firstly, selecting existed data in the corresponding CHS crystal bridge growth model database based on an equivalent particle radius, a stored ambient temperature, and an environmental high and low humidity cycle condition of the crystal particle to be predicted, respectively, and calculating the critical caking cycle according to experience calculation equations, wherein a result obtained by calculation is a predicted critical caking cycle of the crystal particle to be predicted. The present disclosure has characteristics of time-saving, convenience, good universality, and high prediction accuracy, which can quickly predict the critical caking cycle of multi-particle crystal particle products under different humidity storage conditions within a week, resulting in greatly reducing time costs and providing guidance for storage of industrial crystal particle products.

Methods for predicting critical caking cycle of crystal particle

A method for preparing a new crystalline form of &#x3b3;-aminobutyric acid, including the steps of: S1: preparing a &#x3b3;-aminobutyric acid solution at an initial concentration of 0.5-1.0 g/mL by adding crude &#x3b3;-aminobutyric acid to water; adding an additive to the &#x3b3;-aminobutyric acid solution, raising the temperature to 50-80&#xb0; C., stirring to produce a clear solution; and S2: obtaining a suspension by evaporating water from the product of S1 under reduced pressure and at 50-80&#xb0; C.; obtaining a wet product by filtering the suspension; drying the wet product to obtain the new crystalline form of &#x3b3;-aminobutyric acid. The preparation method of the new crystalline form of &#x3b3;-aminobutyric acid is simple, easy to operate, low in energy consumption, economical and environmentally friendly. It is suitable for large-scale industrial production.

Crystalline form of gamma-aminobutyric acid and preparation method thereof

The present invention discloses a &#x3b3;-aminobutyric acid hemihydrate crystal, its molecular formula is CHNO.0.5HO. It also discloses a method of preparing a &#x3b3;-aminobutyric acid hemihydrate crystal, including first adding crude &#x3b3;-aminobutyric acid to water to prepare a &#x3b3;-aminobutyric acid suspension at an initial concentration of 1.2-2.0 g/mL; then stirring the suspension at a constant temperature of 5-10&#xb0; C. for 6-12 hours, followed by filtering and drying to obtain the &#x3b3;-aminobutyric acid hemihydrate crystal. The &#x3b3;-aminobutyric acid hemihydrate crystal is stable, does not easily absorb moisture and agglomerate, and is convenient for further processing and use. The crystal has a large main particle size, uniform particle size distribution, high bulk density, good flowability, and a purity of &#x2265;99%. The preparation method of the crystal according to the present invention is simple, easy to operate, highly efficient and low in energy consumption, and is suitable for large-scale industrial production.

Gamma-aminobutyric acid hemihydrate crystal and preparation method thereof

A novel crystalline form is defined by diffraction angle 2&#x3b8;&#xb0; of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04&#x2dc;0.3 g/ml, stirring the suspension at 40&#x2dc;50&#xb0; C. for a period of time, and then cooling to 5&#x2dc;15&#xb0; C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

Crystalline form of cefamandole nafate compound, preparation and preparing method thereof

This invention provides a new preparation method of Clopidogrel Hydrogen Sulfate spherical crystal form I, using single 2-butanol as solvent, controlling the concentration, addition way and addition speed of sulfuric acid used to salify to shorten the process time, thus separating out Clopidogrel Hydrogen Sulfate from solution system stably with spherality. And the Clopidogrel Hydrogen Sulfate obtained complies with the requirements of the follow-up process on residual solvent, bulk density and mobility.

Method for preparing spherical Clopidogrel Hydrogen Sulfate polymorph I

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 30&#x2dc;45&#xb0; C. to form a solution, whose concentration is controlled within 0.05&#x2dc;0.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 3&#x2dc;5 times (in volume) of that of the solvent; followed by cooling the solution down to 0&#x2dc;10&#xb0; C. at a rate of 0.2&#x2dc;1&#xb0; C./min; continuing to stir for 1&#x2dc;3 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

Crystal form of Cefathiamidine compound and preparation method therefor

Growing community of inventors

Tianjin, China

Junbo Gong